Raymond James & Associates’s Rentokil RTO Stock Holding History

Raymond James & Associates’s Portfolio RTO Stock Details RTO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	$7.3M	Sell	292,847 -50,158	-15%	-$1.49M	﹤0.01%	1409
2024 Q2	$10.2M	Buy	343,005 +8,071	+2%	+$224K	0.01%	1149
2024 Q1	$10.1M	Buy	334,934 +50,968	+18%	+$1.41M	0.01%	1149
2023 Q4	$8.12M	Buy	283,966 +19,872	+8%	+$584K	0.01%	1236
2023 Q3	$9.78M	Sell	264,094 -62,016	-19%	-$2.37M	0.01%	1048
2023 Q2	$12.7M	Sell	326,110 -22,210	-6%	-$870K	0.01%	922
2023 Q1	$12.7M	Buy	348,320 +63,187	+22%	+$1.99M	0.01%	895
2022 Q4	$8.78M	Buy	+285,133	New	+$8.85M	0.01%	1063

Other funds holding RTO

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

GCM

Gates Capital Management New York $3.66B AUM 12.63% 1-Year Est. Return

Brown Advisory Baltimore, Maryland $60.9B AUM 15.24% 1-Year Est. Return

Schroder Investment Management Group London, United Kingdom $122B AUM 29.27% 1-Year Est. Return

Voss Capital Houston, Texas $1.88B AUM 1.03% 1-Year Est. Return

Aristotle Capital Management Los Angeles, California $47.8B AUM 13.38% 1-Year Est. Return

RRAM

River Road Asset Management Louisville, Kentucky $8.99B AUM 12.83% 1-Year Est. Return

Manulife (Manufacturers Life Insurance) Canada, Ontario, Canada $116B AUM 26.37% 1-Year Est. Return

Harvey Partners Tarrytown, New York $1.26B AUM 64.44% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Raymond James & Associates's RTO Position: Q3 2024 in Review

Raymond James & Associates reduced its Rentokil (RTO) stake by 15% in Q3 2024, selling an estimated $1.49M and leaving 292,847 shares worth $7.3M. The position accounts for ﹤0.01% of the portfolio, ranked #1409.

Raymond James & Associates first reported a position in RTO in Q4 2022 and has held it in 8 quarters since. The position peaked at $12.7M in Q2 2023. 220 funds tracked by Wall St. Rank hold RTO as of Q3 2024.

Raymond James & Associates held 292,847 shares of Rentokil worth $7.3M as of Q3 2024.
Raymond James & Associates sold 50,158 Rentokil shares in Q3 2024, an estimated $1.49M.
Rentokil made up ﹤0.01% of Raymond James & Associates's portfolio in Q3 2024, its #1409 holding.
Raymond James & Associates first reported a position in Rentokil in Q4 2022 and has held it in 8 quarters since.
Raymond James & Associates's Rentokil position peaked at $12.7M in Q2 2023.
220 funds tracked by Wall St. Rank held Rentokil as of Q3 2024.

Based on Raymond James & Associates's 13F filing for Q3 2024, filed 18 Oct 2024.